Q-omics provides the consensus-scored NBPF9 profile across patient tissues and cancer cell-line models. NBPF9 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, NBPF9 is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, NBPF9 RNA expression shows 21,057 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight ACC, HNSC, and UVM as cancer lineages where NBPF9 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NBPF9 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NBPF9 survival associations across molecular data types. NBPF9 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NBPF9 RNA expression–survival associations across cancer types. High NBPF9 expression shows unfavorable associations in ACC, UVM, LGG, CESC and KICH, but favorable associations in BRCA. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for NBPF9 RNA expression.
This table summarizes NBPF9 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for NBPF9. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NBPF9 shows higher tumor expression in HNSC, KIRC, COAD, KIRP, BLCA and BRCA. The HNSC box plot shows higher NBPF9 RNA expression in tumor versus normal tissue (log2 FC = +0.683, t-test p < 0.001).
This table shows molecular features associated with NBPF9 in patient tissues and cancer cell lines. In patient samples, NBPF9 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, NBPF9 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in SKIN and LARGE_INTESTINE.
